Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 11/20 | 0.48 |
| ▸ | MAPK12 | P53778 | 11/20 | 0.48 |
| ▸ | MAPK11 | Q15759 | 11/20 | 0.48 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.46 |
| ▸ | CDK8 | P49336 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.42 |
| ▸ | TNF | P01375 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4250862 | 0.93 | MAPK14 (0.49) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL16398841 | 0.91 | GAA (0.44) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL15006786 | 0.88 | GAA (0.42) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL4071373 | 0.85 | MAPK14 (0.41) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL4139540 | 0.82 | MEN1 (0.40) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL1410655 | 0.81 | MAPK14 (0.56) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL16279275 | 0.81 | RAF1 (0.37) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL4076105 | 0.80 | KDM4C (0.41) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL15007855 | 0.80 | MAPK14 (0.37) | MAPK14MAPK13MAPK12MAPK11MAPK9 | |
| SCHEMBL16279857 | 0.79 | GAA (0.39) | MAPK14MAPK13MAPK12MAPK11MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270350-A1 | Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives | PFIZER INC. | 2009-10-29 | — | — | US | disclosed |
| EP-1987022-A1 | PYRIDINONE PYRAZOLE UREA AND PYRIMIDINONE PYRAZOLE UREA DERIVATIVES | Pfizer Products Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007091176-A1 | PYRIDINONE PYRAZOLE UREA AND PYRIMIDINONE PYRAZOLE UREA DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270350-A1 | Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives | PDXK, UMPS, CDK2 | MAPK14 117/4885MAPK13 130/4885MAPK12 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.